134566 - Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer.pdf (270.6 kB)
Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer: from discovery to implementation
journal contribution
posted on 2023-05-20, 06:30 authored by Varnai, R, Koskinen, LM, Mantyla, LE, Szabo, I, Liesel FitzgeraldLiesel Fitzgerald, Sipeky, CProstate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines. Based on this work, we suggest that one of the most promising approaches to improve clinical predictive capacity of pharmacogenomic biomarkers in docetaxel treatment of prostate cancer is the use of compound, multigene pharmacogenomic panels defined by specific clinical outcome measures. In conclusion, we discuss the challenges of integrating prostate cancer pharmacogenomic biomarkers into the clinic and the strategies that can be employed to allow a more comprehensive, evidence-based approach to facilitate their clinical integration. Expanding the integration of pharmacogenetic markers in prostate cancer treatment procedures will enhance precision medicine and ultimately improve patient outcomes.
History
Publication title
GenesVolume
10Issue
8Article number
599Number
599Pagination
1-23ISSN
2073-4425Department/School
Menzies Institute for Medical ResearchPublisher
M D P I AGPlace of publication
SwitzerlandRights statement
Copyright 2019 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/Repository Status
- Open